Effects of long-term administration of low-dose FTY720 on survival of murine cardiac allograft

Abstract

This study examined the effect of long-term administration of low-dose FTY720 on survival of murine cardiac allograft and the possible mechanism. Murine models of abdominal heterotopic heart transplantation were established. Low-dose FTY720 (0.3 mg/kg) was administrated to the animals 4 days before the transplantation of cardiac allografts until the occurrence of rejection or the observation terminals. The animals without FTY720 treatment and those with syngeneic cardiac grafts transplanted served as controls. The mean survival time (MST) of grafts, and T lymphocyte subsets in grafts, peripheral blood and lymphoid organs were measured by histopathological examination or flow cytometry, and compared among groups. The results showed that the MST of allografts in FTY720-treated mice was more than 40 days, significantly longer than that in the untreated group (MST=8 days, P<0.01). After the long-term administration of FTY720, the proportion of CD4⁺ and CD8⁺ lymphocytes in peripheral blood was diminished significantly, but the proportion of CD4⁺ lymphocytes was increased in mesenteric lymph nodes (MLNs) and spleen. Immunofluorescence staining revealed that the infiltration of CD4⁺ and CD8⁺ lymphocytes in allografts was significantly inhibited after long-term administration of low-dose FTY720. It was concluded that low-dose long-term administration of FTY720 could promote T lymphocytes in lymphatic organs and decrease their infiltration in allografts, resulting in the inhibition of rejection and the long-term survival of allografts.

Keywords

FTY720 / immunosuppressant / heart transplantation / rejection / lymphocyte

References

[1] MinD.I., MonacoA.P.. Complications associated with immunosuppressive therapy and their management. Pharmacotherapy, 1991, 11(5): 119S-125S

[2] FujitaT., InoueK., YamamotoS., et al.. Fungal metabolites. Part 11. A potent immunosuppressive activity found in Isaria sinclairii metabolite. J Antibiot (Tokyo), 1994, 47(2): 208-215

[3] BrinkmannV., ChenS., FengL., et al.. FTY720 alters lymphocyte homing and protects allografts without inducing general immunosuppression. Transplant Proc, 2001, 33(1–2): 530-531

[4] Tedesco-SilvaH., LorberM.I., FosterC.E., et al.. FTY720 and everolimus in de novo renal transplant patients at risk for delayed graft function: results of an exploratory one-yr multicenter study. Clin Transplant, 2009, 23(5): 589-599

[5] SilvaH.T.Jr., FelipeC.R., Abbud-FilhoM., et al.. The emerging role of Brazil in clinical trial conduct for transplantation. Am J Transplant, 2011, 11(7): 1368-1375

[6] PfeilschifterW., Czech-ZechmeisterB., SujakM., et al.. Treatment with the immunomodulator FTY720 does not promote spontaneous bacterial infections after experimental stroke in mice. Exp Transl Stroke Med, 2011, 3: 2

[7] AkiF.T., KahanB.D.. A new kid on the block for transplant immunosuppression. Expert Opin Biol Ther, 2003, 3(4): 665-681

[8] BohlerT., WaiserJ., SchuetzM., et al.. FTY720 exerts differential effects on CD4+ and CD8+ T-lymphocyte subpopulations expressing chemokine and adhesion receptors. Nephrol Dial Transplant, 2004, 19(3): 702-713

[9] ZhangQ., ChenY., FairchildR.L., et al.. Lymphoid sequestration of alloreactive memory CD4 T cells promotes cardiac allograft survival. J Immunol, 2006, 176(2): 770-777

[10] ZhuP., ChenY.F., ChenX.P., et al.. Mechanisms of survival prolongation of murine cardiac allografts using the treatment of CTLA4-Ig and MR1. Transplant Proc, 2008, 40(5): 1618-1624

[11] StewartS., WintersG.L., FishbeinM.C., et al.. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transplant, 2005, 24(11): 1710-1720

[12] FocosiD., VistoliF., BoggiU.. Rejection of the kidney allograft. N Engl J Med, 2011, 364(5): 485-486

[13] BurrellB.E., BishopD.K.. Th17 cells and transplant acceptance. Transplantation, 2010, 90(9): 945-948

[14] KwonM.J., WangR., MaJ., et al.. PKC-theta is a drug target for prevention of T cell-mediated autoimmunity and allograft rejection. Endocr Metab Immune Disord Drug Targets, 2010, 10(4): 367-372

[15] anchez-FueyoA., StromT.B.. Immunologic basis of graft rejection and tolerance following transplantation of liver or other solid organs. Gastroenterology, 2011, 140(1): 51-64

[16] BorelJ.F.. Pharmacology of cyclosporine (sandimmune). IV. Pharmacological properties in vivo. Pharmacol Rev, 1990, 41(3): 259-371

[17] European FK506 Multicentre Liver Study Group.. Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. Lancet, 1994, 344(8920): 423-428

[18] ChibaK., HoshinoY., SuzukiC., et al.. FTY720, a novel immunosuppressant possessing unique mechanisms. I. Prolongation of skin allograft survival and synergistic effect in combination with cyclosporine in rats. Transplant Proc, 1996, 28(2): 1056-1059

[19] TanakaT., TakaharaS., HatoriM., et al.. A novel immunosuppressive drug, FTY720, prevents the cancer progression induced by cyclosporine. Cancer Lett, 2002, 181(2): 165-171

[20] NagaharaY., IkekitaM., ShinomiyaT.. Immunosuppressant FTY720 induces apoptosis by direct induction of permeability transition and release of cytochrome c from mitochondria. J Immunol, 2000, 165(6): 3250-3259

[21] SuzukiS., LiX.K., EnosawaS., et al.. A new immunosuppressant, FTY720, induces bcl-2-associated apoptotic cell death in human lymphocytes. Immunology, 1996, 89(4): 518-523

[22] HenningG., OhlL., JuntT., et al.. CC chemokine receptor 7-dependent and -independent pathways for lymphocyte homing: modulation by FTY720. J Exp Med, 2001, 194(12): 1875-1881

[23] MandalaS., HajduR., BergstromJ., et al.. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science, 2002, 296(5566): 346-349

[24] MatloubianM., LoC.G., CinamonG., et al.. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature, 2004, 427(6972): 355-360

[25] PappuR., SchwabS. R., CornelissenI., et al.. Promotion of lymphocyte egress into blood and lymph by distinct sources of sphingosine-1-phosphate. Science, 2007, 316(5822): 295-298

[26] ChibaK., YanagawaY., MasubuchiY., et al.. FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. I. FTY720 selectively decreases the number of circulating mature lymphocytes by acceleration of lymphocyte homing. J Immunol, 1998, 160(10): 5037-5044

[27] YanagawaY., MasubuchiY., ChibaK.. FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats, III. Increase in frequency of CD62L-positive T cells in Peyer’s patches by FTY720-induced lymphocyte homing. Immunology, 1998, 95(4): 591-594

[28] AndersenM.H., SchramaD., Thor StratenP., et al.. Cytotoxic T cells. J Invest Dermatol, 2006, 126(1): 32-41

[29] MurphyK.M., ReinerS.L.. The lineage decisions of helper T cells. Nat Rev Immunol, 2002, 2(12): 933-944

[30] SuzukiS., EnosawaS., KakefudaT., et al.. A novel immunosuppressant, FTY720, with a unique mechanism of action, induces long-term graft acceptance in rat and dog allotransplantation. Transplantation, 1996, 61(2): 200-205

[31] SugitoK., InoueM., IkedaT., et al.. Effect of FTY720 and ex vivo graft irradiation in rat small bowel transplantation: apoptosis of crypt cells and lymphocytes. Transplant Proc, 2007, 39(10): 3432-3435

[32] LiQ., LiF.. Effects of different dose of FTY720 on lymphocyte cell cycle arrest in cardiac transplantation model of rats. Immunopharmacol Immunotoxicol, 2010, 32(4): 680-687

[33] PinschewerD.D., OchsenbeinA.F., OdermattB., et al.. FTY720 immunosuppression impairs effector T cell peripheral homing without affecting induction, expansion, and memory. J Immunol, 2000, 164(11): 5761-5770

[34] XieJ.H., NomuraN., KoprakS.L., et al.. Sphingosine-1-phosphate receptor agonism impairs the efficiency of the local immune response by altering trafficking of naive and antigen-activated CD4+ T cells. J Immunol, 2003, 170(7): 3662-3670